Search
Banoxantrone
go.drugbank.com/drugs/DB04975InvestigationalBanoxantrone is a highly selective bioreductive drug that is activated in, and is preferentially toxic to, hypoxic cells in tumours. … Banoxantrone was also efficacious in tumour models when administered in combination with either cisplatin or chemoradiation. [A3115]
Halazepam
go.drugbank.com/drugs/DB00801ApprovedIllicitWithdrawn[A1212] This drug is no longer marketed in the United States, and was withdrawn by _Schering_, its manufacturer, in 2009.[L6226, L6229] … [A1212, A178114] It has been shown to be less toxic than chlordiazepoxide or diazepam.
Niflumic acid
go.drugbank.com/drugs/DB04552InvestigationalNiflumic acid is an analgesic and anti-inflammatory agent used in the treatment of rheumatoid arthritis.
Dovitinib
go.drugbank.com/drugs/DB05928InvestigationalDovitinib is an orally active small molecule that exhibits potent inhibitory activity against multiple RTKs involved in tumor growth and angiogenesis. … Chiron currently has three ongoing Phase I clinical trials for dovitinib.
Phenothrin
go.drugbank.com/drugs/DB13717InvestigationalCategories: Compounds used in a research, industrial, or household settingIL15-NK Cell
go.drugbank.com/drugs/DB15725InvestigationalIn particular, incubation with IL-15 allows NK cells to lyse a broad range of fresh and cultured tumor targets that the cell is not normally sensitive to.
Bevirimat
go.drugbank.com/drugs/DB06581InvestigationalBevirimat, also known as PA-457 or YK-FH312, is investigated in clinical trials for treating HIV infection. Bevirimat is a solid. … They also show profound effects on scalp and body hair in humans. Bevirimat targets the protein gag-pol polyprotein.
Thiamylal
go.drugbank.com/drugs/DB01154ApprovedVet approvedA barbiturate that is administered intravenously for the production of complete anesthesia of short duration, for the induction of general anesthesia, or for inducing a hypnotic state.
Nifedipine
go.drugbank.com/drugs/DB01115ApprovedInvestigational[A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972. … [A190273] The most popular of the third generation dihydropyridines is [amlodipine].[A190273] Nifedipine was granted FDA approval on 31 December 1981.[L11383]